CYCN - Cyclerion Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
CYCN price evolution
CYCN
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $7.57 | $9.11 | $5.64 | $7.17 |
| Short term investments | ||||
| Net receivables | $0.1 | |||
| Inventory | ||||
| Total current assets | $8.02 | $9.86 | $7.11 | $8.34 |
| Long term investments | $5.35 | $5.35 | ||
| Property, plant & equipment | $1.13 | $1.17 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $5.35 | $5.35 | $2.98 | $3.12 |
| Total investments | $5.35 | $5.35 | ||
| Total assets | $13.37 | $15.21 | $10.1 | $11.46 |
| Current liabilities | ||||
| Accounts payable | $1.2 | $0.81 | $1.86 | $3.92 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $2.09 | $2.34 | $4.95 | $7.53 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2.09 | $2.34 | $4.95 | $7.53 |
| Shareholders' equity | ||||
| Retained earnings | -$264.42 | -$262.72 | -$270.29 | -$266.11 |
| Other shareholder equity | -$0.01 | -$0.02 | -$0.02 | -$0.02 |
| Total shareholder equity | $11.29 | $12.87 | $5.15 | $3.92 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $7.57 | $13.38 | $53.96 | $54.4 |
| Short term investments | ||||
| Net receivables | $0.1 | $0.1 | $0.13 | |
| Inventory | ||||
| Total current assets | $8.02 | $14.82 | $55.46 | $58.5 |
| Long term investments | $5.35 | $3.84 | ||
| Property, plant & equipment | $1.22 | $1.47 | $50.27 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $5.35 | $3.26 | $3.87 | $56.88 |
| Total investments | $5.35 | $3.84 | ||
| Total assets | $13.37 | $18.08 | $59.33 | $115.38 |
| Current liabilities | ||||
| Accounts payable | $1.2 | $2.97 | $1.83 | $1.44 |
| Deferred revenue | ||||
| Short long term debt | $6.8 | |||
| Total current liabilities | $2.09 | $7.63 | $11.09 | $16.95 |
| Long term debt | $38.93 | |||
| Total noncurrent liabilities | $38.93 | |||
| Total debt | $45.73 | |||
| Total liabilities | $2.09 | $7.63 | $11.09 | $55.88 |
| Shareholders' equity | ||||
| Retained earnings | -$264.42 | -$259.15 | -$215.08 | -$163.43 |
| Other shareholder equity | -$0.01 | -$0.02 | -$0.02 | -$0.03 |
| Total shareholder equity | $11.29 | $10.45 | $48.25 | $59.49 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $0.02 | $0.58 | $0.89 | $3.77 |
| Selling, general & administrative | $1.77 | $2.13 | $3.36 | $3.27 |
| Total operating expenses | $1.79 | $6.01 | $4.24 | $7.04 |
| Operating income | -$1.79 | -$6.01 | -$4.24 | -$7.04 |
| Income from continuing operations | ||||
| EBIT | -$1.79 | $7.46 | -$4.24 | -$7.04 |
| Income tax expense | ||||
| Interest expense | -$0.1 | -$0.11 | -$0.06 | -$0.09 |
| Net income | ||||
| Net income | -$1.69 | $7.57 | -$4.18 | -$6.95 |
| Income (for common shares) | -$1.69 | $7.57 | -$4.18 | -$6.95 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.63 | $3.94 | $2.3 | |
| Cost of revenue | ||||
| Gross Profit | $1.63 | $3.94 | $2.3 | |
| Operating activities | ||||
| Research & development | $1.51 | $31.49 | $37.64 | $56.41 |
| Selling, general & administrative | $8.13 | $14.5 | $20.62 | $28.82 |
| Total operating expenses | $12.95 | $46 | $59.14 | $83.56 |
| Operating income | -$12.95 | -$44.37 | -$55.2 | -$81.27 |
| Income from continuing operations | ||||
| EBIT | -$5.62 | -$44.37 | -$51.63 | -$77.8 |
| Income tax expense | ||||
| Interest expense | -$0.36 | -$0.29 | $0.02 | |
| Net income | ||||
| Net income | -$5.26 | -$44.08 | -$51.65 | -$77.8 |
| Income (for common shares) | -$5.26 | -$44.08 | -$51.65 | -$77.8 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$1.69 | $7.57 | -$4.18 | -$6.95 |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.1 | $0.16 | $0.38 | $0.43 |
| Total cash flows from operations | -$1.54 | -$6.93 | -$6.55 | -$6.21 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | ||||
| Effect of exchange rate | $0 | $0 | $0 | |
| Change in cash and equivalents | -$1.54 | $3.47 | -$1.53 | -$6.21 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$5.26 | -$44.08 | -$51.65 | -$77.8 |
| Operating activities | ||||
| Depreciation | $0.07 | $0.47 | $2.3 | |
| Business acquisitions & disposals | $10.4 | |||
| Stock-based compensation | $1.07 | $6.25 | $9.61 | $14.99 |
| Total cash flows from operations | -$21.25 | -$40.61 | -$36.52 | -$72.49 |
| Investing activities | ||||
| Capital expenditures | $1.46 | $0.02 | ||
| Investments | ||||
| Total cash flows from investing | $10.4 | $1.46 | $0.02 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $5.02 | $0.03 | $30.79 | $24.58 |
| Net borrowings | $3.51 | |||
| Total cash flows from financing | $5.02 | $0.03 | $30.79 | $28.09 |
| Effect of exchange rate | $0.01 | $0 | $0 | -$0.01 |
| Change in cash and equivalents | -$5.81 | -$40.58 | -$4.27 | -$44.39 |
News
Fundamentals
| Market cap | $6.85M |
|---|---|
| Enterprise value | -$717.58K |
| Shares outstanding | 2.47M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$5.62M |
| EBIT | -$5.62M |
| Net Income | -$5.26M |
| Revenue Q/Q | -100.00% |
| Revenue Y/Y | -100.00% |
| P/E ratio | -1.30 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | 0.13 |
| EV/EBIT | 0.13 |
| P/S ratio | N/A |
| P/B ratio | 0.61 |
| Book/Share | 4.57 |
| Cash/Share | 3.06 |
| EPS | -$2.13 |
|---|---|
| ROA | -41.99% |
| ROE | -63.34% |
| Debt/Equity | 0.18 |
|---|---|
| Net debt/EBITDA | 0.98 |
| Current ratio | 3.85 |
| Quick ratio | 3.85 |